Sat, Jul 26, 2014, 9:55 AM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

YM BioSciences, Inc. Ordinary S Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • mdv_92126 mdv_92126 Sep 17, 2005 9:56 PM Flag

    News this weekend!

    These results were formally presented on February 25th, 2005 at the �European High-Grade Glioma Meeting� in Regensburg, Germany.
    Phase II Trial Results
    The trial included 20 children who had been treated surgically for their glioma and had also received radiation and mono chemotherapy or combination chemotherapy treatment. They were entered into the trial WHEN ALL PRIOR TREATMENTS HAD FAILED and progression had been documented by MRI assessment. One child was determined to be ineligible and was withdrawn.
    At the time of the conference, 17 of the 19 patients were available for evaluation at eight weeks after induction therapy. Of the six children (35.3%) in the trial who were reported to have responded to treatment, five had stable disease and one was evaluated as a partial response.
    OF THE SIX PATIENTS DIAGNOSED WITH INTRINSIC PONS GLIOMA AT PRIMARY TUMOUR DIAGNOSIS, FOUR CHILDREN (66%) RESPONDED TO TREATMENT WITH THE ANTIBODY.

 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.